Published in World J Gastroenterol on October 21, 2005
Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver (2012) 2.35
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser (2000) 70.59
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med (1995) 8.51
Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology (2000) 2.19
Effects of obesity and caloric intake on biliary lipid metabolism in man. J Clin Invest (1975) 2.17
The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med (1999) 2.05
Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. Fertil Steril (2002) 1.63
Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol (2005) 1.49
Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol (2003) 1.44
Regulation of the diurnal rhythm of rat liver beta-hydroxy-beta-methylglutaryl coenzmye A reductase activity by insulin, glucagon, cyclic AMP and hydrocortisone. Arch Biochem Biophys (1974) 1.40
The mechanism of increased gallstone formation in obese human subjects. Surgery (1976) 1.29
Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J (2002) 1.28
Plasma insulin, serum lipids and lipoproteins in gall stone disease in non-insulin dependent diabetic subjects: a case control study. Gut (1990) 1.27
Increased prevalence of clinical gallbladder disease in subjects with non-insulin-dependent diabetes mellitus. Am J Epidemiol (1990) 1.24
Plasma lipids and insulin in gall stone disease: a case-control study. Br Med J (Clin Res Ed) (1984) 1.21
Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. J Clin Invest (1979) 1.18
Gender differences in serum leptin levels in humans. Biochem Mol Med (1996) 1.13
Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Horm Metab Res (2003) 1.06
Impaired biliary lipid secretion in obese Zucker rats: leptin promotes hepatic cholesterol clearance. Am J Physiol Gastrointest Liver Physiol (2001) 1.06
Leptin promotes biliary cholesterol elimination during weight loss in ob/ob mice by regulating the enterohepatic circulation of bile salts. J Biol Chem (2002) 1.06
Non-HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb (2004) 1.01
Polymorphisms in the leptin receptor gene, body composition and fat distribution in overweight and obese women. Int J Obes Relat Metab Disord (2001) 1.00
Bile lipid secretion in obese and non-obese individuals with and without gallstones. Clin Sci (Lond) (1985) 0.99
Hepatic cholesterol metabolism in human obesity. Hepatology (1997) 0.99
Obesity, leptin, and the brain. N Engl J Med (1996) 0.99
Genetic determinants of variation in gallbladder disease in the Mexican-American population. Genet Epidemiol (1999) 0.93
Effect of insulin on basal and cholecystokinin-stimulated gallbladder motility in humans. J Hepatol (1998) 0.92
Diabetes and hyperlipidemia correlate with gallbladder contractility in leptin-related murine obesity. J Gastrointest Surg (2003) 0.92
Relationship of serum leptin concentration and other measures of adiposity with gallbladder disease. Hepatology (2001) 0.87
Decreased gallbladder response in leptin-deficient obese mice. J Gastrointest Surg (2002) 0.86
Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol (Oxf) (2003) 0.85
High prevalence of cholelithiasis in a low income Mexican population: an ultrasonographic survey. Arch Med Res (1997) 0.85
Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes Metab (2003) 0.85
Identification of insulin-responsive regions in the HMG-CoA reductase promoter. Biochem Biophys Res Commun (2004) 0.85
Leptin and HDL-cholesterol in non-diabetic normotensive subjects. Obes Surg (2001) 0.83
Gallbladder motility in agouti-yellow and leptin-resistant obese mice. J Surg Res (2003) 0.82
Serum leptin and lipid profiles in Thai obese and overweight subjects. Int J Vitam Nutr Res (2001) 0.82
Restoration of gallstone susceptibility by leptin in C57BL/6J ob/ob mice. J Lipid Res (2003) 0.82
Plasma leptin and the cholesterol saturation of bile are correlated in obese women after weight loss. J Nutr (2002) 0.82
Strong association between gallstones and cardiovascular disease. Am J Gastroenterol (2005) 2.43
Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol (2005) 1.49
High ghrelin and obestatin levels and low risk of developing fatty liver. Ann Hepatol (2010) 1.47
Diagnostic value of the copper/zinc ratio in hepatocellular carcinoma: a case control study. J Gastroenterol (2003) 1.45
Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann Hepatol (2004) 1.40
Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev (2010) 1.38
Hepatocellular carcinoma. An overview. Ann Hepatol (2006) 1.29
The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology (2013) 1.27
Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int (2007) 1.24
Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol (2010) 1.21
Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology (2008) 1.16
Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 1.12
Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer (2005) 1.11
Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscess. Cochrane Database Syst Rev (2009) 1.09
Endoscopic submucosal dissection in dogs in a World Gastroenterology Organisation training center. World J Gastroenterol (2010) 1.04
Liver involvement in severe human influenza a H1N1. Ann Hepatol (2010) 1.01
Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol (2007) 1.00
Anabolic-androgenic steroids and liver injury. Liver Int (2007) 1.00
High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol (2012) 0.97
Hepatic manifestations of Epstein-Barr viral infection. Ann Hepatol (2005) 0.96
Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol (2008) 0.94
Eosinophilic gastroenteritis: a review. Dig Dis Sci (2007) 0.94
Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol (2006) 0.93
Role of diet in cholesterol gallstone formation. Clin Chim Acta (2006) 0.93
Learning curve in a Western training center of the circumferential en bloc esophageal endoscopic submucosal dissection in an in vivo animal model. Diagn Ther Endosc (2011) 0.93
Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol (2008) 0.92
Association among C-reactive protein, Fatty liver disease, and cardiovascular risk. Dig Dis Sci (2007) 0.92
Association between cholecystectomy for gallstone disease and risk factors for cardiovascular disease. Ann Hepatol (2011) 0.90
Hepatic encephalopathy: a review. Ann Hepatol (2004) 0.90
Etiology of liver cirrhosis in Mexico. Ann Hepatol (2004) 0.90
Pregnancy and gallbladder disease. Ann Hepatol (2006) 0.90
Treating nonalcoholic fatty liver disease. Liver Int (2007) 0.89
Hepatobiliary diseases in patients with human immunodeficiency virus (HIV) treated with non highly active anti-retroviral therapy: frequency and clinical manifestations. Ann Hepatol (2005) 0.89
Gallstones are associated with carotid atherosclerosis. Liver Int (2007) 0.89
Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren's syndrome. Ann Hepatol (2007) 0.88
Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. Hepatol Res (2013) 0.88
Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol (2005) 0.87
Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol (2004) 0.86
Hepatocellular carcinoma in Hispanics. Ann Hepatol (2007) 0.85
Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol (2004) 0.85
In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. J Hepatol (2010) 0.85
Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann Hepatol (2008) 0.84
Viral hepatitis infection and insulin resistance: a review of the pathophysiological mechanisms. Salud Publica Mex (2011) 0.84
Smoking is not associated with nonalcoholic fatty liver disease. World J Gastroenterol (2006) 0.84
Zinc sulfate inhibits the enterohepatic cycling of unconjugated bilirubin in subjects with Gilbert's syndrome. Ann Hepatol (2004) 0.83
Prophylactic activated recombinant factor VII in liver resection and liver transplantation: systematic review and meta-analysis. PLoS One (2011) 0.82
Microscopic colitides: a single center experience in Mexico. Int J Colorectal Dis (2007) 0.82
Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann Hepatol (2008) 0.82
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. World J Gastroenterol (2006) 0.82
Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city. Dig Dis Sci (2005) 0.82
IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1. Arch Med Res (2011) 0.82
Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. BMC Gastroenterol (2011) 0.82
[An update on non-alcoholic fatty liver disease]. Rev Invest Clin (2004) 0.82
Biliary stricture caused by portal biliopathy: case report and literature review. Ann Hepatol (2006) 0.82
Plasma leptin and the cholesterol saturation of bile are correlated in obese women after weight loss. J Nutr (2002) 0.82
Autoimmune hepatitis with giant-cell transformation. Ann Hepatol (2009) 0.82
The Amerindian's genes in the Mexican population are associated with development of gallstone disease. Am J Gastroenterol (2004) 0.82
TLR9 mRNA expression is upregulated in patients with active ulcerative colitis. Inflamm Bowel Dis (2010) 0.82
The role of dietary fats in the pathogenesis of gallstones. Front Biosci (2003) 0.81
Alcoholic liver disease. An update. Ann Hepatol (2005) 0.81
Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico. Ann Hepatol (2010) 0.81
Worldwide mortality from cirrhosis. Ann Hepatol (2007) 0.81
Acute liver failure and the Molecular Adsorbents Recirculating System: early experience in a tertiary care hospital in Mexico City. Ann Hepatol (2005) 0.81
Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials (2014) 0.81
Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure. Ann Hepatol (2011) 0.80
[New molecular features of cholestatic diseases of the liver]. Rev Invest Clin (2004) 0.80
Association between serum concentration of apolipoproteins A-I and B with gallbladder disease. Arch Med Res (2003) 0.80
Clinical course and management of acute hepatitis A infection in adults. Ann Hepatol (2012) 0.80
The endocannabinoid system in chronic liver disease. Ann Hepatol (2006) 0.80
Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. Ann Hepatol (2006) 0.80
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med (2006) 0.80
Does HLA-DR7 differentiate the overlap syndrome of auto-immune hepatitis-primary biliary cirrhosis (AIH-PBC) from those with auto-immune hepatitis type 1? Ann Hepatol (2011) 0.80
High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. Inflamm Bowel Dis (2010) 0.80
Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol (2005) 0.79
Metabolic syndrome and nonalcoholic fatty liver disease. The role of endothelial progenitor cells. Ann Hepatol (2013) 0.79
Intestinal flora, probiotics, and cirrhosis. Ann Hepatol (2008) 0.79
Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Ann Hepatol (2013) 0.79
Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol (2010) 0.79
Effect of Helicobacter pylori infection on gastric ghrelin expression and body weight. Rev Gastroenterol Mex (2008) 0.79
Coagulation abnormalities in the cirrhotic patient. Ann Hepatol (2013) 0.79
[Gallbladder disease and obesity]. Gac Med Mex (2005) 0.79
Pathophysiology of ascites and dilutional hyponatremia: contemporary use of aquaretic agents. Ann Hepatol (2007) 0.79
Non-alcoholic fatty-liver disease in pediatric populations. J Pediatr Endocrinol Metab (2007) 0.79
The molecular basis of susceptibility to infection in liver cirrhosis. Curr Med Chem (2007) 0.78
Human leukocyte antigens among primary biliary cirrhosis patients born in Mexico. Ann Hepatol (2009) 0.78
Hepatobiliary diseases and insulin resistance. Curr Med Chem (2007) 0.78
Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann Hepatol (2008) 0.78